ArticleFrontiers in immunology2025
Coinfection with HIV-1 skews iNKT cells toward TCR anergy and limited expansion potential in people with hepatitis C.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatitis C virus (HCV) infection remains a leading cause of morbidity and mortality in people with human immunodeficiency virus (HIV). Liver fibrosis progression is more rapid in people with HIV/HCV coinfection compared to HCV monoinfection and the rate of resolution of liver fibrosis after HCV cure is unknown in people with HIV. Invariant natural killer T (iNKT) cells are enriched in the liver and play important roles in initiating immune responses to hepatotropic pathogens and promoting healing following injury. It was recently reported that the pro-healing CD4+ iNKT cells are preferentially infected and depleted in early HIV infection, but this effect on HCV-related liver disease outcomes is unclear. Methods: Here we examined and compared peripheral blood iNKT cells from people with HIV/HCV coinfection and people with HIV and HCV monoinfection or no infection (controls). We evaluated the iNKT cells' expansion potential and phenotype using an unbiased Uniform Manifold Approximation and Projection (UMAP) and clustering based approach. Results: We observed that circulating iNKT cells from people with HIV and HIV/HCV coinfection have impaired expansion to T-cell receptor (TCR) stimulation. We also observed an enrichment of the CD8+ and CD57+ iNKT subsets, which are thought to represent terminally differentiated iNKT cells. HCV monoinfection on the other hand minimally impacted iNKT phenotypes compared to controls. Discussion: The changes observed in iNKT phenotype and proliferative ability in people with HIV/HCV coinfection suggest an impairment that may be contributing to the enhanced pathogenesis during coinfection and could inform novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.